Last reviewed · How we verify
conventional therapy
conventional therapy is a Small molecule drug developed by October 6 University. It is currently FDA-approved. Also known as: Anti hypertensive druds, anti hyperlipidemic drugs, Conventional therapy, Routine treatment, Adapalene plus doxycycline.
The conventional therapy marketed by October 6 University holds a established position in its therapeutic segment, though specific revenue figures are not disclosed. A key strength lies in the protection of its core composition, which is secured until the patent expiry in 2028. The primary risk to consider is the lack of detailed clinical trial results and primary indication data, which may limit its competitive edge against other therapies in the market.
At a glance
| Generic name | conventional therapy |
|---|---|
| Also known as | Anti hypertensive druds, anti hyperlipidemic drugs, Conventional therapy, Routine treatment, Adapalene plus doxycycline, 4 drug combination (HRZE) |
| Sponsor | October 6 University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Targeted Therapy and Avelumab in Merkel Cell Carcinoma (PHASE1, PHASE2)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conventional therapy CI brief — competitive landscape report
- conventional therapy updates RSS · CI watch RSS
- October 6 University portfolio CI
Frequently asked questions about conventional therapy
What is conventional therapy?
Who makes conventional therapy?
Is conventional therapy also known as anything else?
What development phase is conventional therapy in?
Related
- Manufacturer: October 6 University — full pipeline
- Also known as: Anti hypertensive druds, anti hyperlipidemic drugs, Conventional therapy, Routine treatment, Adapalene plus doxycycline, 4 drug combination (HRZE)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing